The Ozempic ladder reaches 2.0 mg weekly, but doubling from 1.0 to 2.0 mg added only about 0.23 percentage points of HbA1c reduction and 0.9 kg of weight loss. Beyond 1.0 mg, most of the added effect is on weight rather than glucose
Donini LM, Busetto L, Bischoff SC, et al
Patient Counseling Points for Combined Amlodipine and Levothyroxine Use Clear, specific instructions reduce the risk of clinically significant subtherapeutic thyroid replacement
Next-generation agents include CagriSema (semaglutide + cagrilintide, NDA filed December 2025, showing 22.7% weight loss), retatrutide (triple GIP/GLP-1/glucagon agonist, 28.7% weight loss in Phase 3), and orforglipron (oral non-peptide GLP-1, submitted to FDA)
This variation reflects differences in genetic metabolism, body composition, and GLP-1 receptor sensitivity